ERBB2 and invasive breast carcinoma: Herein, we aimed to evaluate the concordance rate of HER2-Low status between CNB and SES samples, especially in HER2 negative tumors, in early-stage invasive breast cancer patients and to investigate its association with clinicopathological features.